Enhancing the Anti-Cancer Immune Response by Combining Radiotherapy and Immunotherapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1122347

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Lung cancer is the biggest cause of cancer related death in Australia. Recently, immune therapies have shown promise by unlocking the body’s own defenses to fight against lung cancer. I aim to maximise the effect of the anti-PD-1 immune therapy by ‘kick-starting’ the immune response with high-precision stereotactic ablative body radiotherapy (SABR). By completing clinical trials and biological research into the combination of therapies I hope to improve outcomes for patients with lung cancer.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2020

Funding Scheme: Early Career Fellowships

Funding Amount: $265,138.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Radiation Therapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biomarkers | clinical trial | immunotherapy | lung cancer | radiotherapy

Related Links